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ABSTRACT
The increasing number of retrospective database studies related
to medication compliance and persistence (C&P), and the inher-
ent variability within each, has created a need for improvement
in the quality and consistency of medication C&P research. This
article stems from the International Society of Pharmacoeconom-
ics and Outcomes Research (ISPOR) efforts to develop a check-
list of items that should be either included, or at least considered,
when a retrospective database analysis of medication compliance
or persistence is undertaken. This consensus document outlines a
systematic approach to designing or reviewing retrospective
database studies of medication C&P. Included in this article are
discussions on data sources, measures of C&P, results reporting,
and even conﬂict of interests. If followed, this checklist should
improve the consistency and quality of C&P analyses, which in
turn will help providers and payers understand the impact of
C&P on health outcomes.
Keywords: compliance, guidelines, persistence, retrospective
databases.
Purpose of this Article
Retrospective databases are increasingly being used to
describe the incidence and prevalence of medication
compliance and persistence (C&P) in a variety of dis-
ease states. The increasing number of studies reﬂects
the growing concern surrounding medication C&P as
well as the need to gain a better understanding of this
widespread health and economic issue. The utility of
these studies is in helping payers and providers see
how medication C&P vary among patients and how
that variation impacts health outcomes. Coupled with
increased reports using retrospective databases is an
expanding variability in the methods used to measure
and analyze medication C&P. The numerous proxy
measures of medication C&P used in these studies cre-
ate a potential inconsistency that hampers the readers’
ability to apply such information to real-life practice.
Improving the quality of these studies would enhance
their value.
To help the readers and designers of such studies,
the International Society of Pharmacoeconomics and
Outcomes Research (ISPOR) charged the ISPOR Med-
ication Compliance and Persistence Special Interest
Group (SIG) to develop a checklist of items that should
be either included, or at least considered, when a ret-
rospective database analysis of medication compliance
or persistence is undertaken. The Analytic Methods
Working Group of this SIG met frequently to deﬁne
the appropriate elements for such a checklist. The
members of this working group consist of researchers,
academicians, and practitioners with a record of pub-
lication and interest in medication C&P and retrospec-
tive database analysis.
Some elements in this checklist were drawn from
other ISPOR efforts related to retrospective databases
and medication compliance. For example, the deﬁni-
tions of compliance and persistence were drawn from
the ISPOR Compliance and Persistence SIG Deﬁnitions
Working Group (http://www.ispor.org/sigs/medication.
asp), and the broader discussion of retrospective data-
base analyses was drawn from the Advisory Panel
Report discussing methodological issues with retro-
spective and claims data studies [1]. Note that the
terms “compliance” and “adherence” are considered
synonyms, while both differ from “persistence.”
Explicit deﬁnitions of compliance and persistence
should, however, be provided by the researcher for
individual studies (as noted later in this article).
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Framework of Checklist
This document, and the accompanying checklist
(Appendix A), can be used together or separately. The
narrative portion reviews each of the sections of a
medication C&P study and provides the reader with
an explanation of the issues relative to that section.
Within each section, we attempt to review the perti-
nent literature and provide the reader with sufﬁcient
information such that she or he would make an
informed evaluation regarding the merits of a particu-
lar study. The accompanying checklist is designed to
prompt the reviewer/reader about certain elements of a
C&P study. (See Table 1 for an overview of the check-
list framework.)
How Should the Checklist Be Used?
This checklist should be used to aid in the evaluation
of a study undergoing peer review or when a
researcher is planning to develop a retrospective data-
base study related to medication C&P. The purpose is
to guide the reader/researcher through a systematic
process to assure that they key issues related to retro-
spective database studies of medication C&P are
addressed. Caution should be exercised, however,
when applying this checklist. It is intended to be a
guideline for either the researcher interested in con-
ducting such a study or the reviewer of such studies to
evaluate key elements of such a paper. The presence or
absence of these elements is likely to affect the quality
of the study; however, the absence of one or more of
the checklist elements should not be interpreted as dis-
crediting the quality of the study. It is up to the
researcher and reviewer to use this checklist solely as a
tool to aid them in their work, not judge it.
Description of Checklist Elements
Title
The title of the study should be descriptive and reﬂect
its purpose. Furthermore, the title should include the
appropriate term(s) as represented by the study. This
would include the retrospective nature of the study, the
population(s) being examined, and the appropriate
measure of compliance or persistence.
Example. Title: “A retrospective analysis of medica-
tion persistence among children taking stimulant
medications for the treatment of attention deﬁcit
hyperactivity disorder (ADHD).”
Abstract
The title should be a short description of the study. The
abstract, presented at the beginning of an article,
should be a short summary of the objectives, methods,
results, and conclusions. Structured abstracts require
the author to follow a speciﬁc format. The purpose
of the structure is to provide a systematic means of
organization. Some journal editors request that the
abstract be “the paper in miniature,” completely self-
contained. The revised Consolidated Standards of
Reporting Trials statement strongly encourages
abstracts to be in a structured format to allow the
reader to locate information more easily and poten-
tially improve the quality of the abstract [2]. In this
vein, the Methods section of the abstract should deﬁne
the types of analyses used, and the Results section
should describe the extent of the ﬁndings using those
methods. The main results of the analyses should be
stated numerically in the abstract. The Conclusion sec-
tion should not overextrapolate the results and should
only reﬂect the true ﬁndings of the study. Be aware that
almost 5% of abstracts contain erroneous information
[3]. Note that abstracts require great attention to accu-
racy because they are more widely available than full
articles.
Introduction Section
The ﬁrst part of the Introduction section should review
the literature in the area of study. This scientiﬁc back-
ground should allow the reader to understand the
rationale for the study being conducted and describe
the nature of the problem or issue that the study
intends to investigate. Furthermore, the scope and
severity of the problem should be addressed using a
clear review of the fundamental literature related to
the topic being addressed, including appropriate clin-
ical and health economic literature, along with the
C&P literature.
Objectives and Deﬁnitions
The selection of an appropriate study objective is
important because it drives the study design and vari-
ables being measured. These are important issues to
address because the design and methods for the study
should allow the researcher to measure appropriately
the compliance or persistence variable and fulﬁll the
objectives of the study.
Therefore, in this section of a study, the reader
should ﬁnd clearly stated objectives and an indication
Table 1 Elements of the checklist
1. Title/Abstract
2. Introduction
3. Objectives/Deﬁnitions
4. Design and Methods
a. Design
b. Data Sources
c. Inclusion/Exclusion criteria
d. Measurement of Compliance
e. Statistical Analyses
5. Presentation and Discussion of Findings
a. Results
b. Discussion/Conclusion
6. Disclosure of Potential Conﬂicts of Interest
Checklist for Medication Compliance Studies 5
of the primary outcome of interest. The author should
indicate when compliance or persistence is the primary
“outcome” of interest (the dependent variable), or
being used as an explanatory or control variable to
explain variance in an outcome. In either case, the
author should provide explicit deﬁnitions of compli-
ance or persistence based on a published deﬁnition
with appropriate literature reference. Recommended
deﬁnitions have been promulgated by the ISPOR Med-
ication Compliance and Persistence Deﬁnitions Group
and are available on the ISPOR Web site (http://
www.ispor.org/sigs/medication.asp).
Design and Methods
This section is designed to help the reader/researcher
focus on many of the key elements of a well-conducted
retrospective database analysis involving medication
compliance. The importance of linking the appropriate
study design to the objectives and compliance or per-
sistence measure is emphasized, as is the importance of
clearly delineating the population being studied.
Design
The three major types of study designs are exploratory,
descriptive, and explanatory. An exploratory study of
medication compliance or persistence does not involve
hypothesis-testing and is often qualitative in nature.
Descriptive studies of medication C&P may employ
qualitative or quantitative methods to describe the
medication-use patterns of a population An explana-
tory study is designed to investigate the relationship
between medication C&P and other variables. The
design of the explanatory study is, however, crucial to
explaining the casual nature of the relationships
studied.
Many database analyses employ a study design
known as the historical cohort. This study design is
nearly identical to a prospective cohort study, except
that the data have already been collected and are
usually stored in an electronic database. In this study
design, the researcher constructs the cohort by select-
ing patients already treated, meeting certain inclusion/
exclusion criteria. This design may facilitate an exam-
ination of the relationship between C&P and other
variables but limits the researcher’s ability to assess
causation because of the limitations typically associ-
ated with retrospective studies (e.g., selection bias,
missing or incomplete information, or censoring bias).
The design of the study should be clearly stated and
this design should match the objectives of the study.
For example, a longitudinal study using a retrospective
database may allow the researcher to determine the
incidence of noncompliance, whereas a cross-sectional
study only allows the researcher to determine the prev-
alence. Furthermore, a researcher should recognize the
limitations of using retrospective data in establishing
the causal relationship between C&P and other
variables.
Data Sources
A well-described retrospective database analysis
allows the reader to identify the population from
which the sample is drawn. (For a full discussion of the
key elements to deﬁning the population and associated
variables, the reader is referred to the ISPOR Advisory
Panel Report on retrospective databases [1].) The
methods for sampling need to be adequately described
so the reader can infer whether the sample is repre-
sentative of the population of interest. Also, a full
description of the data source is important. The
researcher should clearly indicate whether the data
source is a public or a commercial database, or if it is
not a prescription claims database (e.g., disease regis-
try). The time frame for the data set needs to be
described and the length of study should be clearly
delineated so that an assessment of the appropriateness
of the study period can be made in relation to the
objectives.
To  this  end,  the  researcher  should  clearly  state
the inclusion and exclusion criteria for the study and
describe the rationale for these criteria. To ensure that
the sample represents the population of interest, the
method by which the researcher veriﬁed subjects meet-
ing the inclusion/exclusion criteria must be present and
appropriate. For example, the continuous eligibility
for a prescription beneﬁt during the study period
should be veriﬁed to determine whether patients had
sufﬁcient data to make a valid estimate of compliance
or persistence (i.e., patients need at least two ﬁllings of
a medication to calculate a medication possession
ratio). Furthermore, there should be a description of
the pre-enrollment period and a determination of
whether a subject was truly naive to the drug, if impor-
tant to the study. The investigators should describe
how the subjects were identiﬁed, including a prestudy
period to determine prestudy medication use and
diagnoses.
Other areas for consideration relate to the deﬁni-
tions used to select the subjects for inclusion. For
example, did the researchers use diagnosis codes versus
prescription claims to categorize patients as having
diabetes? Also, if the researchers employed a matching
process (if appropriate to the study design), did they
describe it adequately and was it sufﬁcient in detail to
assure appropriate matching could occur? The purpose
of the matching strategy is to minimize the potential
for selection bias.
The researcher also needs to assure the reader that
every effort was taken to protect the conﬁdentiality of
subjects, such as Institutional Review Board/Ethics
Committee approval or meeting Health Insurance
Portability and Accountability Act guidelines (for US
studies). Coupled with this is evidence that the data
Peterson et al.6
have been appropriately “cleaned” (entries that are
clearly erroneous are eliminated or ﬁxed) and that the
researcher provided evidence for the reliability and
accuracy of the data. The investigators should explain
how cleaning/editing the data set affected eligibility,
often by further excluding speciﬁc types of cases [1].
Measurement of Compliance
The transparency of the measurement of C&P is very
important. The researcher simply stating that the
method of calculating C&P is “proprietary” and can-
not be disclosed is not conducive to scientiﬁc dialogue.
Therefore, the methods for calculating the C&P vari-
able should be clearly described. Every effort should be
made to use standard methods for calculating C&P so
that it is possible to interpret the ﬁndings of the study
in context with other studies. It is important to note
that the measure chosen as the C&P variable should be
consistent with the objective of the study. For example,
researchers interested in measuring compliance rates
should not use a variable that actually measures per-
sistence, or vice versa. There are several methods used
to calculate C&P. The following are just a few. (The
reader is also referred to Steiner et al. [4] or Farmer [5]
for more examples.)
Measures  of  compliance. A variety of methods are
used to estimate a patient’s compliance using retro-
spective databases. One of the most common methods
is to calculate the medication possession ratio (MPR).
When this ratio is calculated across multiple reﬁlls, it
may also be called the continuous measure of adher-
ence (CMA) [6]. These measures are typically calcu-
lated using the basic formula noted below:
Number of Days of Medication Supplied within the
Reﬁll Interval/Number of Days in Reﬁll Interval
This is usually calculated by summing the number
of days supplied for all but the last reﬁll, divided by the
number of days between the ﬁrst and the last reﬁll.
Therefore, at least two ﬁll dates are required to calcu-
late this ratio. Researchers, however, may choose a
ﬁxed time frame for the reﬁll interval rather than using
the last reﬁll as the end point for the reﬁll interval.
Within most US-based prescription claims databases,
the “days supply” is usually included as a data ﬁeld
within each prescription claim (e.g., 60 tablets of a
medication that is taken twice daily would yield a 30-
day supply), along with the dates that the prescription
was ﬁlled or reﬁlled. In some non-US databases, the
researcher may need to estimate the days supply for
each drug by applying the deﬁned daily dose to the
quantity dispensed.
Other methods include a continuous measure of
medication gaps (CMG), in which the sum of the days
in the gaps between reﬁlls in the observation period is
divided by time between the ﬁrst and last ﬁlls. This
estimate provides an indication of the percentage of
time the patient does not have the medication available
for use. For example, the ﬁlling behavior of a cohort of
patients being treated for congestive heart failure may
be highly variable, resulting in numerous gaps in dig-
oxin use. In some cases, the gaps can be negative (early
ﬁll) as well as positive (late ﬁll). The CMG would
require the analyst to add the positive and negative
gaps for the period of observation. This measure pro-
vides an indication of the variability in reﬁll behavior.
An example of a study that used CMG in diabetes
patients is Morningstar et al. [7].
Measure of Persistence
Persistence adds the dimension of time to the analysis
and usually represents the time over which a patient con-
tinues to ﬁll a prescription, or the time from the initial
ﬁlling of the prescription until the patient discontinues
reﬁlling a prescription. The most common time unit is
days, but could also be months or years. One means of
calculating this is the estimated level of persistence
(ELPT) method [8]. This calculation (below) allows the
researcher to determine the percentage of individuals
remaining on therapy (persistent) at a given time. ELPT
may differentiate patients taking a medication sporad-
ically during a deﬁned time frame from those patients
stopping the medication early during the same  time
frame  [8].  The  data  can  be  displayed  on  a persistency
curve, very similar to a Kaplan–Meier curve. The most
common analysis is a Kaplan–Meier life table with dis-
continuation considered as elimination.
Proportion of patients reﬁlling each subsequent pre-
scription with (X*days supplied) from ﬁll n.
Dezii used this measure to help differentiate pa-
tients taking a medication sporadically during a de-
ﬁned time frame versus those patients stopping the
medication early during the same time frame.
Proportion of days covered. The proportion of days
covered (PDC) is a measure of patient compliance that
has been used with increasing frequency [9–13]. The
PDC is calculated as the number of days with drug on-
hand divided by the number of days in the speciﬁed
time interval. The PDC may be multiplied by 100 to
yield a percentage. The numerator of the PDC is not
merely a sum of the “days supplied” by all pre-
scriptions ﬁlled during the period. Rather, ﬁlled pre-
scriptions are evaluated using a set of rules to avoid
double-counting covered days. Thus, the PDC is
always a value between 0 and 1. The denominator for
the PDC is typically a clinically meaningful number of
days that is the same for all intervals and patients (e.g.,
90 days). The PDC can be analyzed as a continuous
measure or divided into categories for use as an ordinal
or dichotomous variable. When measured repeatedly
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and analyzed using appropriate statistical methods for
within-subject repeated measures, the PDC has the
advantage of simultaneously reﬂecting both C&P.
Data based on this approach are frequently described
in a ﬁgure to illustrate time trends.
Other  measures  of  persistence. Alternative analyses
include number of days to discontinuation and
number of prescription reﬁlls over a period of time.
The days to discontinuation is a simple count of days
from the index prescription to the date of the ﬁnal dis-
pensing, although some researchers include the days
for which the ﬁnal ﬁll provided dosing (e.g., ﬁnal
30 days). The number of reﬁlls, usually within
12 months of the index ﬁll, could include patients who
reﬁll long after the allowed 30- or 60-day gap for being
considered nonpersistent. This is a valuable calcula-
tion for drugs that may be used “as needed” without
detriment to the clinical condition (e.g., treatments for
seasonal allergy).
Measurement issues. The researcher needs to account
for the how anomalous values were handled. Some
measures of C&P allow for the calculation of “hyper-
compliant” values (e.g., MPR > 1 or negative gaps).
The researcher should describe how and why these
values were incorporated into the analysis. If an atypi-
cal method is used for calculating compliance, the
researcher should report the rationale for the new
method along with the formula for its calculation. Sim-
ilarly, when the researcher collapses multiple medica-
tions into a single compliance estimate, the rationale
and formula for this variable should be included.
Examples of this are when the average MPR or gap
across different medications is used to estimate overall
compliance. If the researcher uses this strategy, then
the analysis should also control for the inﬂuence that
varying numbers of medications can have on the com-
pliance variable itself.
The Methods section also should explain how the
analysis handled patients who switched to another
medication in the same class (e.g., another phenothi-
azine) or one that is used for the same diagnosis (e.g.,
an atypical antipsychotic) [14]. For example, did the
researcher drop those patients who switched drugs
within the same class, or did the researcher estimate
the “equivalent” dose of the two drugs and allow the
patient to remain in the analysis. Furthermore, there
should be some estimation of whether the method
used for handling this variable was appropriate for
fulﬁlling the study objective. Some researchers have
categorized a drug-therapy switch as nonpersistence
because it involves discontinuation of the initially
selected drug. Nevertheless, because the term “persist-
ence” is typically used to describe a patient’s behavior,
referring to a treatment switch as nonpersistence may
suggest that the patient failed to take the product as
directed even though the patient followed the direc-
tions appropriately.
If the drug is not an oral solid dosage form (e.g.,
capsules or tablets), alternative methods are needed.
For example, the dose of liquid, powdered, injected,
and inhaled drugs may be prescribed in a way that
leaves the patient with an under- or oversupply of drug
at the end of the month. An attempt should be made to
calculate an adjustment for wastage from the dispens-
ing container, particularly for inhaled and injected
drugs. For example, insulin wastage was estimated to
account for higher than expected compliance in one
study [15].
Statistical Analyses
The distribution of the dependent variable must be
considered when selecting an appropriate statistical
test. The researcher should determine the best type of
statistical test based on the type of data and their dis-
tribution. In general, parametric tests are preferred,
but if the assumptions underlying a speciﬁc parametric
test are violated, then a nonparametric equivalent
should be employed. Nonparametric tests should be
employed when
• the data are measured and/or analyzed using a
nominal or ordinal scale of measurement;
• the probability distribution of the statistic is not
normally distributed.
When there is a cap on the MPR (e.g., maximum = 1),
there may be a violation of the normality assumption,
and therefore a nonparametric test should be consid-
ered. Similarly, if all the gaps in a gap analysis are con-
verted to “no gaps” or “0,” this also may violate the
normality assumption. When subjects are categorized
as “compliant” and “noncompliant” (e.g., when using
a cutoff within the MPR to create the categories), a
nonparametric test should also be used.
In general, it is not wise to convert continuous data
to categorical data. Statistically, there is a loss of
power because of a decrease in the number of degrees
of freedom (ANOVA models). Conceptually, dividing
the data into arbitrary categories limits the utility of
the information. It may be appropriate to use categor-
ical data for a logistic regression, but with caution
about the deﬁnition. If continuous data are converted
to categorical data, the rationale for selection of cut-
points should be provided and consistent with existing
evidence for compliance in the selected population.
The point at which discrimination is made for categor-
ical deﬁnitions of compliance versus noncompliance
should have been determined with a sensitivity analy-
sis. An adequate discrimination of a cut-point has been
made for few medications. One example is the need to
take more than 95% of antiretroviral medication doses
to avoid the development of resistance [16]. Few other
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investigations have looked at outcomes above and
below the postulated categories.
Researchers should be careful when using any cat-
egorical cut-point (commonly listed as 80%) unless
they can document the clinical validity of the number
as well as determine that that lower and higher values
differ (sensitivity test). Selection of a cut-point usually
requires information that patients taking more than
this amount of medication have a clinically better
outcome than patients taking less. This is not a statis-
tical test but a clinical test of relevance. There are
very few medications for which a cut-point has been
determined.
If the researcher makes multiple comparisons using
the same data, there should be an adjustment made to
maintain the experiment-wise alpha error at the pre-
speciﬁed level. Examples of appropriate adjustments
include Bonferroni adjustment for multiple compari-
sons or the use of a post hoc test (e.g., least signiﬁcant
difference, Tukey’s, Duncan’s, Scheffe’s) after deter-
mining a signiﬁcant F-value in an ANOVA.
Realistic power and/or sample size calculations
should be described. If the researcher did not achieve
the prespeciﬁed sample size, a recalculation of the
power based on the actual results might be appropri-
ate. There is controversy, however, regarding this
approach. Others suggest that conﬁdence intervals be
calculated so that the readers can interpret the results
on their own [17].
Furthermore, the researchers should make an
attempt to control for bias in the data set. Bias can
come in a variety of forms, including selection bias and
measurement bias. The research should address how
the potential for bias was handled. For example, pro-
pensity scoring is a technique used to control for sys-
tematic differences between groups by reducing the
differences between groups to a single variable [18].
The researchers should explain the variables they
chose to generate the propensity score and the results
of the scoring. The researchers should indicate whether
the covariates used in the process were balanced
between the two groups, and if not, what steps they
took to produce balance.
If the researcher is evaluating an association
between compliance and another variable, he or she
should attempt to control for other variables that may
confound the association being studied. To determine
which variables directly affect compliance and which
variables have mediating effects, the author should
consider statistical techniques that facilitate answering
the question. Such techniques include multivariate
regression. To establish mediation, each variable is
regressed in a hierarchical forward stepwise fashion on
all other variables that precede it in the causal chain.
The risk of misleading results increases as the ratio
of independent variables to the number of patients
increases. Therefore, the researcher should consider
what variables act as confounders and which variables
are covariates and should be controlled for accord-
ingly in an analysis. Typical variables that may con-
found the measure of compliance include cost of
medication, comorbidities, severity of illness (as meas-
ured by the Charlson comorbidity index or the chronic
disease score), sex, and other sociodemographic fac-
tors [19,20]. Before adjusting for any variables, it is
suggested that the researcher undertake a thorough
review of the literature to establish variables that are
known confounders within the disease state being
studied and which covariates may show trends but are
not known confounders. Establishing this a priori will
also help guide the analytical plan. The researcher
should attempt to maintain an alpha at 0.05, recog-
nizing that often we have to deal with small sample
sizes in our studies and that sometimes the analysis is
exploratory in nature.
Presentation and Discussion of Findings
Results
The results section should begin by stating the charac-
teristics of the C&P variable. The reader should know
the distribution of the variable (e.g., normally dis-
tributed) and whether the distribution matches the
intended statistical tests. If not, the researchers should
indicate what adjustments were made to transform it
into a usable variable (e.g., log transformation to
improve normality). The data should have the accom-
panying variability measure (e.g., mean for continuous
data, medians for categorical data, or effect sizes/
conﬁdence intervals). If the data were subjected to
statistical tests, the resulting statistic and associated P-
values and/or conﬁdence intervals should be appropri-
ately displayed. The number of subjects (n) for each
variable should be prominently displayed in all tables
and graphs and the graphs should be constructed with
appropriate scales to avoid misleading the reader.
Discussion
Within the discussion section, there should be a state-
ment of the principal ﬁndings for the primary out-
come, without excessive extrapolation beyond these
results [21]. As such, this is the section of the report
where the researchers place the results into context
with the existing literature. The ﬁndings of this study
should be compared with the ﬁndings of similar stud-
ies, and comparisons between populations, methods,
and results should be made. Also within this section,
the study limitations and their impact on the outcome
of the study should be noted and discussed [2,21,22].
For example, the researchers should discuss the inﬂu-
ence of the decision to retain values or cap values. Evi-
dence of whether the ﬁnal results are inﬂuenced heavily
by retaining versus capping these values is valuable.
Furthermore, this section should include a review of
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the statistical power of the study, and the associated
sample size should be mentioned as well as any source
of bias.
The Discussion section should include an overview
of  the  limitations  of  the  analysis  and  interpretation
of results from a retrospective database analysis. This
includes a need to discuss the external validity of the
results by taking into consideration the population of
patients reviewed and how the inclusion/exclusion cri-
teria may have impacted the results. In particular, the
selection of patients, number of months to ascertain
lack of previous use of medication, and number of
months of follow-up should be defended. If the
patients were selected by diagnostic codes, the accu-
racy of the codes should be supported. Most important
is the need to explain the study design so that the
reader does not perceive an intrinsic bias to favor a
drug or class of drugs. This speaks to a need to address
the internal validity of the study, and the researcher
must openly discuss the limitations inherent in any ret-
rospective analysis and how they apply to this partic-
ular situation.
Lastly, the researcher has the responsibility for plac-
ing the results of the research in context with the exist-
ing information. As such, this section should address,
if appropriate, the implications of the ﬁndings as they
may relate to health-care outcomes or health policy or
how they support the need for further research.
Disclosure of Potential Conﬂicts of Interest
The study should include a statement regarding the
researcher’s potential for conﬂict of interest. Conﬂict
of  interest  refers  to  a  self-interested  ﬁnancial  beneﬁt
a researcher has in the product or technique being
studied [23,24]. Notation of this is particularly impor-
tant where the study has a commercial sponsor with a
vested interest in ﬁnding the superiority of one product
[23,24]. Although disclosure of this nature may not
prevent the bias from being introduced, it allows the
reader to assess the objectivity of the investigators and
their research. Studies that are obviously biased in
design to elicit the most favorable characteristics of the
sponsor’s drug do a disservice to the community of
health-outcomes researchers.
Conclusion
This report summarizes the consensus of international
thought about how to perform retrospective analyses
of administrative databases related to taking medica-
tion. This is a ﬁrst step in the process undertaken by
the ISPOR Medication Compliance and Persistence
SIG. A key to understanding appropriate methodolog-
ical approaches is the adoption of the deﬁnitions of
medication compliance (synonym: adherence) and per-
sistence developed by ISPOR, particularly to acknowl-
edge that they are separate constructs. Working in
coordination with other groups, additional methodo-
logical approaches will be prepared for prospective
studies of medication C&P, as well as economic anal-
yses of these issues. ISPOR will provide this checklist
to journal editors with the expectation that future
research will follow the standardized structure to
allow a reasonable review of manuscripts as well as
comparisons among published reports. Within time,
the current heterogeneity of analyses will become a
more uniform presentation of data to help providers
and payers understand the impact of C&P on health
outcomes.
Source of ﬁnancial support: None. 
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Appendix—Checklist for Assessing/Evaluating 
Medication Compliance and Persistence Studies 
Using Retrospective Databases
Title/Abstract
• The title is descriptive and reﬂective of the pur-
pose of the study.
• The abstract is a short, concise description, com-
mensurate with the journal’s standards.
• Abstract follows a structured format (as appro-
priate to the journal) and includes at least the
following:
 Objectives;
 Methods;
 Results;
 Conclusions.
• The abstract accurately reﬂects the contents of the
study and there are no discrepancies.
Introduction
• The author(s) clearly reviewed fundamental liter-
ature related to topic being addressed.
 Appropriate clinical literature;
 Appropriate compliance and persistence
literature;
 Appropriate health economic literature;
 Other ____________ (specify).
• Objective of study clearly stated.
Objectives and Deﬁnitions
• The objective(s) of the study has been clearly
stated and can be readily identiﬁed as one of the
following:
 Exploratory;
 Descriptive;
 Analytical.
• There is an explicit deﬁnition of the compliance
and persistence variable and the deﬁnition used is
based on a published, accepted deﬁnition.
• Compliance or persistence is the primary “out-
come” of interest or
• Compliance or persistence is being used as an
explanatory or control variable to explain vari-
ance in another outcome.
Design and Methods
Design
• The design is clearly stated.
• The design matches the objectives.
Data Sources
• All of the data sources have been described
adequately.
• The time frame for data has been clearly
stated.
• The methods for sampling the population are well
described.
• The data have been appropriately “cleaned” (i.e.,
erroneous data were ﬁxed or removed).
• There is evidence for the reliability/accuracy of the
data.
Inclusion/Exclusion Criteria
• The inclusion and exclusion criteria for the study
are clearly stated.
• The rationale for these criteria is described.
• The method by which the researchers veriﬁed sub-
jects meeting the inclusion/exclusion criteria is
stated and appropriate.
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• Continuous eligibility for drug beneﬁt during the
study period was veriﬁed.
• Patients had sufﬁcient data to make a valid esti-
mate of compliance.
• For studies of patients who are newly initiated on
a drug regimen, there was an examination of data
from a sufﬁcient pre-enrollment period to ensure
that the subject was truly naive to the drug.
• The duration of the study period is appropriate to
the objectives of the study.
• There is evidence for protecting the conﬁdentiality
of subjects.
• The matching process, if appropriate to the study
design, is well described.
 Matching strategy minimizes the potential for
bias;
 Propensity scores used to control for selection
bias.
Measurement of Compliance
• The methods for calculating the compliance or
persistence variable are clearly described.
• The measurement matches the operational deﬁni-
tion provided earlier.
 Do the objectives indicate that the study is to
measure compliance but persistence is actu-
ally calculated?
• Standard methods are used for calculating
compliance.
 Continuous measure of medication availabil-
ity/medication possession ratio (MPR).
 The researchers explained how they han-
dled values greater than 1.
• Were the values retained or con-
verted to 1?
 Gaps methods (continuous measure of medi-
cation gaps).
 The researchers explained how they han-
dled negative gap values.
• Were the values retained or con-
verted to 0 (no gap)?
 Proportion of days covered.
Standard Methods for Calculating Persistence
• If an atypical method is used for calculating com-
pliance, the rationale/formula for the new method
is provided.
• The researchers provided an appropriate expla-
nation for how patients who switched drugs
within, or between, therapeutic classes were
handled.
• If multiple medications were included within a
single compliance or persistence estimate, the
researchers provided a rationale and/or a formula
for this variable.
 The average of the MPR/gap across the dif-
ferent medications was used.
 The analysis controlled for the inﬂuence of
how many medications were combined into a
single variable.
 Was another variable created to indicate
whether the patient was on one drug for
diabetes versus multiple drugs for diabetes?
 Is there a logical argument for combining
the MPRs? It may be more appropriate to
combine the MPRs for drugs that treat
the same condition (e.g., combining the
MPR for two drugs for diabetes) as
opposed to combining the MPRs for
drugs used for different conditions.
Statistical Analyses
In general, the use of continuous data to measure com-
pliance and persistence are encouraged.
• If continuous data are converted to categorical
data, the rationale for the selection of cut-points
should be provided and consistent with existing
evidence for compliance in the selected population
(e.g., cut-point of 95% may be most appropriate
for antiretrovirals, but 80% may be appropriate
for hypertension).
• The tests are appropriate given the objectives,
design, and the nature of the data.
• Appropriate adjustments for multiple compari-
sons were conducted.
• Appropriate adjustments were made to the anal-
yses if the data were not normally distributed.
• Power and/or sample size calculations are pre-
sented and appropriate.
• There was an attempt to control for selection bias
(e.g., propensity scoring).
• If the researcher is evaluating an association
between compliance or persistence and another
variable, the researcher attempted to control for
other variables that may confound the association
being studied.
Presentation and Discussion of Findings
Results
• The distribution of the compliance or persistence
variable is presented.
• Test statistics and conﬁdence intervals are appro-
priately presented in addition to P-values.
• The number of subjects is clearly identiﬁed in
tables and graphs.
• Graphs were constructed with an appropriate
scale.
Discussion/Conclusion
• The limitations are appropriately noted and the
implications of the limitations are discussed.
 The inﬂuence of the decision to retain values
or cap values is discussed.
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 Power and sample size limitations are
addressed.
• The ﬁndings of this study are placed in the context
of our existing knowledge of the subject.
 Appropriate comparison of the current ﬁnd-
ings to that of similar studies is made.
• The ﬁndings and conclusions are related to the
objectives of the study.
Disclosure of potential conﬂicts of interest
• Potential conﬂicts of interest are disclosed.
